Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(1), С. 364 - 364

Опубликована: Янв. 3, 2025

This review describes our current understanding of the role mitochondria in repurposing anti-diabetes drugs metformin, gliclazide, GLP-1 receptor agonists, and SGLT2 inhibitors for additional clinical benefits regarding unhealthy aging, long COVID, mental neurogenerative disorders, obesity. Metformin, most prominent these diabetes drugs, has been called “Drug Miracles Wonders,” as trials have found it to be beneficial human patients suffering from maladies. To promote viral replication all infected cells, SARS-CoV-2 stimulates liver cells produce glucose export into blood stream, which can cause COVID patients, reduces levels blood, was shown cut incidence rate half recovering SARS-CoV-2. Metformin leads phosphorylation AMP-activated protein kinase AMPK, accelerates import via transporter GLUT4 switches starvation mode, counteracting virus. Diabetes also stimulate unfolded response thus mitophagy, is healthy aging health. were mimic exercise help reduce body weight.

Язык: Английский

---

Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach

Open Forum Infectious Diseases, Год журнала: 2024, Номер 11(9)

Опубликована: Авг. 27, 2024

Abstract While the acute manifestations of infectious diseases are well known, in some individuals, symptoms can either persist or appear after period. Postviral fatigue syndromes recognized with other viral infections and described coronavirus disease 2019 (COVID-19). We have a growing number individuals that for weeks, months, years. Here, we share evidence regarding abnormalities associated postacute sequelae COVID-19 (PASC) therapeutics. describe physiological biochemical seen reporting PASC. several evidence-based interventions to offer patients. It is expected this understanding mechanisms driving PASC benefits certain therapeutics may not only lead better outcomes those but also potential treating postinfectious sequelae.

Язык: Английский

---

Association between underlying health conditions and long COVID among non-hospitalized and hospitalized individuals as modified by health literacy: A multi-center study

Public Health, Год журнала: 2025, Номер 239, С. 87 - 93

Опубликована: Янв. 10, 2025

We investigated the effect modification of health literacy (HL) in ameliorating negative impact underlying conditions (UHC) on long COVID among non-hospitalized and hospitalized survivors. An online cross-sectional study was conducted Vietnam from December 2021 to October 2022. A sample 4507 participants recruited 18 hospitals centers were those aged or older, had contracted COVID-19 for at least 28 days, not acute phase reinfection. Participants reported their symptoms, UHC, literacy, socio-demographics, clinical parameters, battery disability scale, health-related behaviors. The logistic regression models used examine associations interactions. Underlying associated with a higher likelihood (adjusted odds ratio, aOR = 2.10 [1.61, 2.61]; p < 0.001), ones (aOR 2.26 [1.87, 2.73]; 0.001). In participants, HL scores significantly linked reduced experiencing 0.96 [0.95, 0.97]; Furthermore, moderated adverse this group 0.97 [0.94-0.99]; 0.042). although also lower risk 0.99 [0.98-0.99]; 0.036), did mitigate UHC 1.01 [0.99-1.03]; 0.332). individuals, high ameliorated COVID. Such effects observed

Язык: Английский

---

Preliminary Evaluation of a Mindfulness Intervention Program in Women with Long COVID Dysautonomia Symptoms

Brain Behavior & Immunity - Health, Год журнала: 2025, Номер unknown, С. 100963 - 100963

Опубликована: Фев. 1, 2025

The symptom burden for patients with Long COVID-associated dysautonomia is high, yet there are currently no effective treatments. Mindfulness programs reduce psychological and physical symptoms as well inflammatory gene expression in a variety of medical conditions. study aim was to evaluate the effect six-week mindfulness program women COVID symptoms. Using single arm, pre- posttest design, aged 18-54 years orthostatic intolerance suggestive were recruited from center. Participants attended standardized, six-week, virtual program. An active stand test 6-min walk (6MWT) performed at baseline post-intervention. Self-reported measures mental health collected baseline, post-intervention 4 week follow up included composite autonomic score (COMPASS-31), perceived stress (PSS), anxiety (GAD7), depression (PHQ8), COVID-19 event specific distress (IES-R), fatigue (FSI), sleep (ISI), well-being (MHC-SF), resilience (CD-RISC 10), quality life (SF-20). effects on conserved transcriptional response adversity (CTRA) examined by next-generation sequencing dried whole blood samples. Twenty participants enrolled mean age 39.9 (range 21-52 years). No significant changes observed or 6MWT. A reduction insomnia severity (ISI: 16.6 vs. 13.6; p = 0.001) post-intervention, but scores reverted toward levels 4-week follow-up. improvements seen symptoms, anxiety, stress, depression, well-being, related distress. Pro-inflammatory CTRA decreased significantly pre-to (p 0.004). Declines most among those 3 positive events 0.01), followed 2 0.04) 1 0.05). did not vary function recent illness, hospitalization, demographic characteristics, general history. virtual, may improve dysautonomia. While objective improvement observed, our findings suggest favorable intervention antiviral biology decrease expression. Nonetheless, this population very more attention needed provide multi-modal clinical therapies population.

Язык: Английский

---

Ten sessions of hyperbaric oxygen versus sham treatment in patients with long covid (HOT-LoCO): a randomised, placebo-controlled, double-blind, phase II trial

BMJ Open, Год журнала: 2025, Номер 15(4), С. e094386 - e094386

Опубликована: Апрель 1, 2025

Objectives To evaluate if 10 sessions of hyperbaric oxygen treatments (HBOTs) improve short- and long-term health related quality life, symptoms physical performance in long covid patients compared with placebo. Design Parallel, randomised, placebo-controlled, double-blind trial. Setting Single-centre, university hospital, Sweden. Participants Previously healthy subjects aged 18–60 years, diagnosed were included. We excluded pregnant women, RAND-36 (role limitations due to (RP) functioning (PF)) above 70, diabetes, hypertension contraindications for HBOT. Interventions Subjects randomly assigned HBOT or sham (placebo) over 6 weeks. involved 100% oxygen, 2.4 bar, 90 min, placebo medical air, 1.34–1.2 bar. Randomisation (1:1) was done electronically, blocks stratified by sex disease severity. investigators blinded allocation. Primary secondary outcome measures endpoints changes from baseline PF RP at 13 Efficacy analysed on an intention-to-treat basis. Harms evaluated according the actual treatment given. Results Between 15 September 2021 20 June 2023, 80 (65 men) enrolled randomised (40 each group). The trial is completed. primary endpoint analysis included 79 39 control). At weeks, both groups showed improvement, no significant difference between (least square mean (LSD), 0.63 (95% CI −7.04 8.29), p=0.87) (LSD, 2.35 −5.95 10.66), p=0.57). Harms: 43 adverse events (AEs), most commonly cough chest pain/discomfort, occurred 19 (49%) group 38 AEs 18 (44%) group, one serious AE death group. Conclusions did not show more short-term benefits than patients. Both improved, a notable difference. has favourable harm profile. Trial registration number ClinicalTrials.gov ( NCT04842448 ), EudraCT (2021-000764-30). funded Vetenskapsrådet (2022-00834), Region Stockholm (2020-0731, 2022-0674), Hjärt-Lungfonden OuraHealth Oy.

Язык: Английский

---

LEF1-AS1 Deregulation in the Peripheral Blood of Patients with Persistent Post-COVID Symptoms

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(10), С. 4806 - 4806

Опубликована: Май 17, 2025

Long COVID denotes the persistence of symptoms after acute SARS-CoV-2 infection lasting for at least two months without another identifiable cause. Affecting an estimated 15% COVID-19 patients, long manifests in a wide range symptoms. Despite extensive research on its one-year effects, limited data exist beyond 12 months. Due to different manifestations COVID, diagnosis can be challenging. Identifying potential mechanistic contributors and biomarkers would highly valuable. Recent studies have highlighted noncoding RNAs (ncRNAs) as disease stratification COVID-19. Specifically, we recently identified miR-144-3p subset lncRNAs candidates assessing severity outcomes This nested case–control study extends such investigations 98 patients recruited 18 hospitalization, exploring relationship between circulating ncRNA expression persistent While miR-144-3p, HCG18, lncCEACAM21 did not differ symptomatic asymptomatic LEF1-AS1 was downregulated peripheral blood mononuclear cells (PBMCs) patients. Of note, multiple isoforms LEF1 sense transcript levels were reduced negatively correlated with relevant clinical markers. further are needed, our discoveries offer new perspectives management COVID.

Язык: Английский

---

COVID de larga duración

Medicina Clínica, Год журнала: 2025, Номер 165(2), С. 107009 - 107009

Опубликована: Май 23, 2025

---

Supporting Evidence For Pulmonary Rehabilitation in the Treatment of Long COVID

Respiratory Care, Год журнала: 2024, Номер 69(11), С. 1477 - 1479

Опубликована: Окт. 25, 2024

Long COVID has quickly emerged as a global health challenge, and we continue to investigate the effects from plethora of symptoms surrounding condition. The prevalence varies across globe, 31% in North America, 44% Europe, 51% Asia.1 Clinicians researchers around world are working better understand COVID. Although there have been close 600 clinical trials including COVID,2 underlying biological mechanisms affecting mostly unknown. People with reported over 200 symptoms, dyspnea fatigue consistently being noted most frequently. Vaes et al3 described that majority people unusual up 6 months after onset COVID-related symptoms. As result, 83% subjects moderate-to-poor health, almost half (49%) indicated they still experienced moderate-to-severe functional limitations.3 Another study showed 12 hospitalization COVID-19 53% dyspnea, 60% were experiencing fatigue.4 It's well established many these patients will need continued treatment their diagnosis, rehabilitation shown promise for ameliorating negative In this issue Respiratory Care, Asimakos al5 studied impact supervised program on authors used multidisciplinary aerobic exercise resistance training, education, … Correspondence: Dave M Burnett PhD RRT, University Kansas Medical Center, Department Care Diagnostic Science, 3901 Rainbow Boulevard, Mail stop 1013, City KS 66160. E-mail: dburnett{at}kumc.edu

Язык: Английский

---

Ten Sessions of Hyperbaric Oxygen Versus Sham Treatment in Patients with Long COVID (HOT-LoCO): A Randomised, Placebo Controlled, Double-Blind, Phase II Trial

Опубликована: Янв. 1, 2024

Язык: Английский

---

A Real-Life Study in Patients Newly Diagnosed with Autoimmune Hashimoto’s Thyroiditis: Analysis of Asthenia as Admission Complaint

Life, Год журнала: 2024, Номер 14(11), С. 1380 - 1380

Опубликована: Окт. 27, 2024

Background: Amid the large panel of autoimmune thyroid diseases, Hashimoto’s thyroiditis (HT) represents a major point across multidisciplinary daily practice. When it comes to clinical picture, particularly in regard asthenia (also described as “fatigue” or “decreased energy”), differential diagnosis is challenging, and meticulous anamnesis should be backed up by focused lab investigations. Our objective was analyze newly diagnosed patients with HT relationship presence an admission complaint. Methods: This retrospective, multi-centric, real-life study conducted secondary endocrine units (university hospitals) from July 2022 2023. The exclusion criteria were COVID-19 infection; active malignancy, etc. Results: cohort (N = 120) included group (AS, 49.2%) non-AS similar age (49.3 ± 14.7 vs. 47.1 14.8 y, p 0.426). Headache more frequent AS (35.6% 18%, 0.03). Thyroid function HT-related antibodies assays between groups show no correlation serum total cholesterol triglycerides, respectively. TSH levels did not vary among sub-groups (p 0.701). One third studied population affected hypothyroidism (TSH > 4.5 μIU/mL), being seen at higher rate (39%) (23%). Total positively correlated patients’ (r 0.180, 0.049) triglycerides 120; r 0.324, < 0.001), found only 0.246, 0.006, respectively, 0.319, 0.001). Conclusions: analysis pinpointed fact that, practice, complaint seems less indicator underlying dysfunction level against without full picture thyrotoxicosis myxoedema.

Язык: Английский

---